SYMPOSIA

More documents

Recommendations

Info

Poster Presentations [PP-068] Ref. No: 303 Varenicline induced psychotic disorders: A case report İkbal İnanlı, İbrahim Eren, Tahsin Etli Konya Eğitim ve Araştırma Hastanesi Beyhekim Psikiyatri Kliniği, Konya, Turkey E-mail: ikbalcivi@yahoo.com Varenicline is a new agent, commonly used to assist individuals with smoking cessation. There is an increase in case reports of psychiatric disorders induced or activated by using the agent. Due to the agent’s mechanism of actions, it is possible to make this correlation. Patients who have a mental illness or high-risk persons should be careful about using this drug. In this report, the case of a psychotic disorder induced by varenicline is presented. Key words: Psychotic disorder, smoking cessation, varenicline Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S162 [PP-069] Ref. No: 309 Affective disorders and catatonia: Report of two cases Feride Büyükşahin, Jülide Güler, Başak Ünübol, Hüseyin Ünübol, Alper Ünal Erenkoy Mental Health Education and Research Hospital, İstanbul, Turkey E-mail: basakctf@hotmail.com Catatonia refers to a broad group of movement abnormalities usually associated with schizophrenia, but also found in other disorders such as mania, depression, many neurological disorders (especially those involving the basal ganglia, limbic system, diencephalon, and frontal lobes), systemic metabolic disorders, and toxic drug states. Catatonia is often neglected when screening and examining psychiatric patients. Undiagnosed catatonia can increase morbidity and mortality, illustrating the need to effectively screen patients for presence of catatonia, as well as their response to treatment. We describe the clinical presentation of catatonia in a 32 year-old woman with schizoaffective disorder and in a 25 year-old woman with severe psychotic depression. Key words: Catatonia, mood disorders, depression Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S162 [PP-070] Ref. No: 224 The relationship of incarceration, past suicide attempts, depression, anxiety and attention deficit hyperactivity disorder in cases of anti-social personality disorder Hakan Balıbey 1 , Türker Türker2, Zülküf Perdeci 1 , Nalan Bayar 1 , Mehmet Boran Evren 1 1 Department of Psychiatry Ankara Military Hospital, Ankara, Turkey 2 Department of Public Health Division of Epidemiology Gulhane Military Medical Faculty, Ankara, Turkey E-mail: hbalibey@gmail.com Bacgrounds and Objective: Even though attention deficit/hyperactivity disorder (ADHD) has been considered as a childhood disorder for a long time, currently it is widely accepted that this is a disorder that continues well into adulthood. Attention deficit hyperactivity disorder (ADHD) is a chronic developmental psychiatric disorder, which starts in early childhood, although its primary symptoms can still be observed in adulthood. The main symptoms are attention loss, impulsiveness, and hyperactivity which result in mental, social, and educational/occupational problems in adulthood (1). The current study aimed to study the relationship of incarceration, suicide attempts, depression, anxiety, and attention deficit hyperactivity disorder in men, who had been diagnosed with antisocial personality disorder (APD). There are previous studies in the literature for equivalent diagnoses (2,3). METHODS: A total of 80 subjects, 44 of whom were diagnosed with antisocial personality disorder according to the DSM-IV-TR diagnostic criteria in Ankara Military Hospital psychiatry clinic and 36 controls, who did not have a psychiatric diagnosis were included in the study. The subjects had been administered a semistructured interview form for identifying their demographic properties, criminal history, and past suicide attempts. The subjects had also S162 Bulletin of Clinical Psychopharmacology, Vol: 21, Supplement: 2, 2011 - www.psikofarmakoloji.org
Bulletin of Clinical Psychopharmacology, Vol: 21, Supplement: 2, 2011 - www.psikofarmakoloji.org Poster Presentations been given the Wender-Utah rating scale, Hamilton anxiety scale, and Hamilton depression scales. The diagnosis of anti-social personality disorder has been corroborated by a second mental health professional for all such cases. Results: There was a statistically significant difference between the Wender-Utah test scores of the APD group and the control group (p
Page 1 and 2:
With Contributions of
Page 3 and 4:
Turkish Association for Psychopharm
Page 5 and 6:
Nihat ALPAY Rüstem AŞKIN Ömer AY
Page 7 and 8:
NOVEMBER 23, 2011 WEDNESDAY TIME HA
Page 9 and 10:
NOVEMBER 25, 2011 FRIDAY AT A GLANC
Page 11 and 12:
13.30 15.00-16.00 17.30-19.30 17.30
Page 13 and 14:
09.00-10.30 PS-04: Adult attention
Page 15 and 16:
20.30-22.30 KC-01: Biostatistics -
Page 17 and 18:
09.00-10.30 PS-09: From preclinical
Page 19 and 20:
09.00-10.30 PS-10: Will glutamaterg
Page 21 and 22:
09.00-10.30 JS-05: Indian Psychiatr
Page 23 and 24:
NOVEMBER 26, 2011 SATURDAY 09.00-10
Page 25 and 26:
NOVEMBER 27, 2011 SUNDAY 09.00-10.3
Page 27 and 28:
Author(s) Abstracts of the Invited
Page 29 and 30:
Author(s) Abstracts of the Invited
Page 31 and 32:
Author(s) Poster Presentation 16 A.
Page 33 and 34:
Author(s) Poster Presentation 60 Ba
Page 35:
Author(s) Poster Presentation 108 O
Page 38 and 39:
Abstracts of the Invited Speakers O
Page 40 and 41:
Abstracts of the Invited Speakers p
Page 42 and 43:
Abstracts of the Invited Speakers D
Page 44 and 45:
Abstracts of the Invited Speakers R
Page 46 and 47:
Abstracts of the Invited Speakers [
Page 48 and 49:
Abstracts of the Invited Speakers H
Page 50 and 51:
Abstracts of the Invited Speakers m
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Abstracts of the Invited Speakers d
Page 58 and 59:
Abstracts of the Invited Speakers e
Page 60 and 61:
Abstracts of the Invited Speakers d
Page 62 and 63:
Abstracts of the Invited Speakers S
Page 64 and 65:
Abstracts of the Invited Speakers o
Page 66 and 67:
Abstracts of the Invited Speakers N
Page 68 and 69:
Abstracts of the Invited Speakers I
Page 70 and 71:
Abstracts of the Invited Speakers E
Page 72 and 73:
Abstracts of the Invited Speakers G
Page 74 and 75:
Abstracts of the Invited Speakers T
Page 76 and 77:
Abstracts of the Invited Speakers A
Page 78 and 79:
Abstracts of the Invited Speakers l
Page 80 and 81:
Abstracts of the Invited Speakers E
Page 82 and 83:
Page 84 and 85:
Abstracts of the Invited Speakers i
Page 86 and 87:
Abstracts of the Invited Speakers
Page 88 and 89:
Page 90 and 91:
Abstracts of the Invited Speakers A
Page 92 and 93:
Abstracts of the Invited Speakers P
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Abstracts of the Invited Speakers O
Page 100 and 101:
Abstracts of the Invited Speakers T
Page 102 and 103:
Abstracts of the Invited Speakers e
Page 104 and 105:
Abstracts of the Invited Speakers o
Page 106 and 107:
Abstracts of the Invited Speakers S
Page 108 and 109:
Abstracts of the Invited Speakers C
Page 110 and 111:
Page 112 and 113:
Abstracts of Oral Presentations [SO
Page 114 and 115:
Abstracts of Oral Presentations Mat
Page 116 and 117: Abstracts of Oral Presentations wit
Page 118 and 119: Abstracts of Oral Presentations pat
Page 120 and 121: Abstracts of Oral Presentations ade
Page 122 and 123: Abstracts of Oral Presentations eff
Page 124 and 125: Turkish Association for Psychopharm
Page 126 and 127: Poster Presentations behavior by ex
Page 128 and 129: Poster Presentations [PP-005] Ref.
Page 130 and 131: Poster Presentations fulfilling the
Page 134 and 135: Poster Presentations eating disorde
Page 136 and 137: Poster Presentations Conclusion: Th
Page 138 and 139: Poster Presentations had no treatme
Page 140 and 141: Poster Presentations 80 mg/day (dos
Page 154 and 155: Poster Presentations Based on the r
Page 160 and 161: Poster Presentations study, the Cro
Page 168 and 169: Poster Presentations motivations fo
Page 172 and 173: Poster Presentations 4. Şükrü Ka
Page 176 and 177: Poster Presentations References: 1.
Page 178 and 179: Poster Presentations when meeting a
Page 180 and 181: Poster Presentations MADRS and HAM-
Page 182 and 183: Poster Presentations in terms of co
Page 184 and 185: Poster Presentations schizophrenia
Page 186 and 187: Poster Presentations ascending dopa
Page 188 and 189: Poster Presentations study. The inc
Page 190 and 191: Poster Presentations and Spaniards.
Page 192 and 193: Poster Presentations patients, and
Page 200 and 201: Poster Presentations 22.7%, bipolar
Page 202 and 203: Poster Presentations future, we exp
Page 204 and 205: Poster Presentations of action, ami
Page 206 and 207: Poster Presentations pharmacologica
Page 208 and 209: (±)-3-4-methylenedioxymethamphetam
Page 210 and 211: Panic symptoms S122 Paroxetine S156
Page 212 and 213: Etli T. S162 Evren C. S80, S154, S1
show all

SYMPOSIA

Create successful ePaper yourself

Delete template?

Save as template?